Presence of Direct Thrombin Inhibitors Can Affect the Results and Interpretation of Lupus Anticoagulant Testing

Department of Pathology, Pritzker School of Medicine, the University of Chicago, Chicago, IL 60637, USA.
American Journal of Clinical Pathology (Impact Factor: 2.51). 11/2005; 124(4):586-93. DOI: 10.1309/7RYUN5DRK4WCH3PM
Source: PubMed


In vitro experiments were conducted to determine whether the direct thrombin inhibitors argatroban and lepirudin can interfere with the results of lupus anticoagulant (LA) testing. Concentration-response curves were generated to calculate the concentration of anticoagulant that prolongs the activated partial thromboplastin time (aPTT) to 75 seconds (2.5 times the baseline average). Corresponding concentrations of anticoagulant were added to plasma samples before running dilute Russell viper venom tests (DRVVTs) and LA-sensitive aPTTs (PTT-LAs). Because the DRVVT test system contains an antiheparin agent, DRVVT results were not prolonged in the presence of heparin. With argatroban added to normal plasma samples, neither the DRVVT percent correction of ratio nor the DRVVT test/confirm ratio were elevated, but when added to LA-positive plasma, some false-negative results were observed. Lepirudin increased the DRVVT percent correction of ratio and the DRVVT test/confirm ratio into a range that could lead to false-positive identifications of LAs. In sharp contrast to the DRVVT test system, distinction between LA-positive and LA-negative plasma samples was maintained and possibly even enhanced in the platelet neutralization procedure correction phase of the PTT-LA test system.

Full-text preview

Available from:
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lupus anticoagulants are antibodies with heterogenous specificities to phospholipids. They have been associated with clinical syndromes consisting of thrombosis and recurrent fetal loss. To address questions about the laboratory assay aspects of lupus anticoagulants. This review is intended for clinicians managing lupus anticoagulant testing in clinical laboratories. Published literature on lupus anticoagulants, with emphasis on laboratory assay methods. Although there are published criteria for confirming the presence of a lupus anticoagulant, there is no consensus on assay methods for lupus anticoagulant testing. The mixing study is a useful screening test for lupus anticoagulants, but it may have limited utility. Clinical context may necessitate the performance of factor assays in addition to lupus anticoagulant testing to rule out factor deficiency or factor-specific inhibitor. Additionally, the presence of different anticoagulants may affect the reliability of lupus anticoagulant assays. Lupus anticoagulants are an independent risk factor for thrombosis. It may be useful to use different assays when there is clinical suspicion for a lupus anticoagulant. When testing for lupus anticoagulants, clinicians must carefully consider the clinical context because factor assays may also be indicated.
    No preview · Article · Jul 2007 · Archives of pathology & laboratory medicine
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antiphospholipid syndrome (APLS) is among the most common acquired blood protein defects that have been identified as leading to thrombosis. This article describes the laboratory diagnosis of APLS, including the detection of lupus anticoagulants, anticardiolipin antibodies, and subtypes of antiphospholipid antibodies.
    Full-text · Article · Mar 2008 · Hematology/Oncology Clinics of North America
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Argatroban is a direct thrombin inhibitor approved for the treatment of heparin-induced thrombocytopenia (HIT) type II. Argatroban is predominantly metabolized in the liver. It is widely believed that no dosage adjustment is required in patients with renal insufficiency, making it a preferred agent in patients on renal replacement therapy (Reddy and Grossman, Ann Pharm 2005;39:1601-1605). The elimination half-life of argatroban is approximately 50 min. Lupus anticoagulants can cause baseline elevation of the PTT and hence it is difficult to monitor the effects of anticoagulants such as heparin, lepirudin, or argatroban in patients with antiphospholipid antibody syndrome. Heparin levels may be used as an alternative for heparin monitoring but plasma levels of argatroban are not commercially available. A chromogenic antifactor IIa assay could be useful for monitoring argatroban in the presence of a lupus anticoagulant, but it is not widely available at present. We report a patient with end-stage renal disease, maintained on peritoneal dialysis with HIT, who demonstrated a markedly prolonged half-life when treated with argatroban despite the discontinuation of therapy. This case also demonstrates the lack of guidelines for the monitoring of argatroban therapy in the presence of an underlying lupus anticoagulant.
    Full-text · Article · Mar 2008 · American Journal of Hematology
Show more